Marc Wilson - Crinetics Pharmaceuticals Chief Officer
| CRNX Stock | USD 35.21 0.05 0.14% |
Executive
Mr. Marc Wilson is Chief Financial Officer of the Company. Prior to Crinetics, Mr. Wilson was Vice President of Finance and Accounting and Chief Accounting Officer at Cidara Therapeutics, Inc., a publiclytraded biotechnology company, from September 2014 to January 2018. Prior to Cidara, from October 2010 to August 2014, Mr. Wilson was Director of Accounting and Controller at Trius Therapeutics, a biopharmaceutical company, until its acquisition by Cubist Pharmaceuticals. Prior to Trius, Mr. Wilson worked at Neurocrine Biosciences, Inc. from 2007 to 2010. Mr. Wilson began his career in 2001 with PricewaterhouseCoopers LLP and is a certified public accountant since 2018.
| Age | 45 |
| Tenure | 7 years |
| Address | 6055 Lusk Boulevard, San Diego, CA, United States, 92121 |
| Phone | 858 450 6464 |
| Web | https://www.crinetics.com |
Latest Insider Transactions
Wilson earned a bachelor’s degree in Economics and Accounting from the College of the Holy Cross.Marc Wilson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Marc Wilson against Crinetics Pharmaceuticals stock is an integral part of due diligence when investing in Crinetics Pharmaceuticals. Marc Wilson insider activity provides valuable insight into whether Crinetics Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Crinetics Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Crinetics Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Marc Wilson over six months ago Acquisition by Marc Wilson of 19056 shares of Crinetics Pharmaceuticals at 9.28 subject to Rule 16b-3 | ||
Marc Wilson over six months ago Disposition of 19056 shares by Marc Wilson of Crinetics Pharmaceuticals at 9.28 subject to Rule 16b-3 | ||
Marc Wilson over six months ago Disposition of 25000 shares by Marc Wilson of Crinetics Pharmaceuticals at 20.02 subject to Rule 16b-3 | ||
Marc Wilson over a year ago Exercise or conversion by Marc Wilson of 10000 shares of Crinetics Pharmaceuticals subject to Rule 16b-3 |
Crinetics Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2429) % which means that it has lost $0.2429 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4026) %, meaning that it created substantial loss on money invested by shareholders. Crinetics Pharmaceuticals' management efficiency ratios could be used to measure how well Crinetics Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2025. Return On Capital Employed is likely to drop to -0.36 in 2025. At this time, Crinetics Pharmaceuticals' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 382 M in 2025, whereas Other Assets are likely to drop 1.09 in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Carlos Bais | Inhibrx | N/A | |
| Steven JD | Cytokinetics | 66 | |
| Jeffrey Jensen | Inhibrx | N/A | |
| Shan Wu | Viridian Therapeutics | N/A | |
| Josep Garcia | Inhibrx | N/A | |
| Ram PharmD | Regenxbio | 49 | |
| Matthew JD | Lyell Immunopharma | 49 | |
| Sue Browne | Passage Bio | N/A | |
| Charbel PharmD | Inhibrx | N/A | |
| PharmD Mordwinkin | Kezar Life Sciences | 43 | |
| Wes Trotter | Kronos Bio | N/A | |
| Margaux Bennett | Kronos Bio | N/A | |
| Rocio Hoyos | Kronos Bio | N/A | |
| Virginia MBA | Alector | N/A | |
| Gary MD | Alector | 63 | |
| Fang Zhang | Structure Therapeutics American | N/A | |
| Xichen Lin | Structure Therapeutics American | 51 | |
| Bryan Selby | Lyell Immunopharma | N/A | |
| Kristina MPH | Alector | N/A | |
| Diane Weiser | Cytokinetics | N/A | |
| Eric Terhaerdt | Cytokinetics | N/A | |
Management Performance
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.24 |
Crinetics Pharmaceuticals Leadership Team
Elected by the shareholders, the Crinetics Pharmaceuticals' board of directors comprises two types of representatives: Crinetics Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Crinetics. The board's role is to monitor Crinetics Pharmaceuticals' management team and ensure that shareholders' interests are well served. Crinetics Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Crinetics Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeff Knight, Chief Officer | ||
| James Hassard, Chief Officer | ||
| Adriana MBA, Chief Officer | ||
| Gayathri Diwakar, Head Relations | ||
| Stephen Betz, Co-Founder, Vice President - Biology | ||
| Dana MD, Chief Officer | ||
| Robert MD, Senior Affairs | ||
| Marc Wilson, Chief Officer | ||
| Kevin Capps, Head Property | ||
| Scott Struthers, CEO, Co-Founder, Director | ||
| Alan MD, Chief Endocrinologist | ||
| Garlan Adams, General Secretary | ||
| Chris MBA, Chief Officer | ||
| Marc CPA, Chief Officer |
Crinetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Crinetics Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (295.25) % | ||||
| Current Valuation | 2.46 B | ||||
| Shares Outstanding | 92.74 M | ||||
| Shares Owned By Insiders | 1.79 % | ||||
| Shares Owned By Institutions | 98.21 % | ||||
| Number Of Shares Shorted | 7.38 M | ||||
| Price To Earning | (12.03) X | ||||
| Price To Book | 3.92 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.